This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Celgene buys $12.75mm of Agios' stock in post-IPO PIPE
22 Aug 2013
Agios Pharmaceuticals Inc. (developing drugs for cancer and inborn errors of metabolism) grossed $12.75mm through the sale of 708k common shares at $18 each to affiliates of strategic partner Celgene Corp. The private placement was made in conjunction with Agios' $98.6mm initial public offering, in which the company sold 5.89mm share at $18. Celgene and Agios have been partners since 2010, when Celgene took an option to Agios' early-stage cancer metabolism programs. In addition to the private placement, Celgene had previously taken part in Agios' Series B round, which closed at the same time as the companies struck up their alliance.
Private Investment in Public Equity
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?